AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT04134897
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 825 mg/m2, bid, per os, only on days of radiation (Monday through Friday)
Trial: NCT01229228
Drug: Naproxen Test
RxNorm normalized name: Naproxen
DrugBank: Naproxen (DB00788)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 200-mg single dose
Trial: NCT01229228
Drug: Naproxen Test
RxNorm normalized name: Naproxen
DrugBank: Naproxen (DB00788)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 400-mg (2 x 200-mg)
Trial: NCT01229228
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single dose
Trial: NCT00189085
Drug: simvastatin and ezetimibe
RxNorm normalized name: simvastatin and ezetimibe
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01699997
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal spray with placebo solution
Trial: NCT00996840
Drug: SB-681323 Intravenous 7.5 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7.5 mg SB-681323 Intravenous administration infused over 24 hours
Trial: NCT00996840
Drug: SB-681323 Intravenous 7.5mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7.5 mg SB-681323 Intravenous administration infused over 4 hours
Trial: NCT01973283
Drug: Antidepressant Medication
RxNorm normalized name: ANTIDEPRESSANTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: If patient has a history of non-response or cannot tolerate escitalopram and/or duloxetine, then they will be treated openly with an approved antidepressant.
Trial: NCT03467620
Drug: Placebo oral capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of one oral placebo capsule daily for a duration of 12 weeks
Trial: NCT02872103
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo subcutaneous injection on Day 2 of the first TA chemotherapy cycle. TA chemotherapy treatments are part of standard-of-care and not the study.
Trial: NCT02941367
Drug: Sulfonylurea
RxNorm normalized name: Sulfonylurea
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: tablet~Route of administration: oral
Trial: NCT03941548
Drug: CTP-543 Matching Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered as tablets to aid treatment masking.
Trial: NCT02081963
Drug: Amikacin
RxNorm normalized name: amikacin
DrugBank: Amikacin (DB00479)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Nebulized 0.2g of amikacin and 2 mL of normal saline twice a day for 14 days in combination with standard treatment.
Trial: NCT02081963
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebulized 3 mL of normal saline twice a day for 14 days in combination with standard treatment.
Trial: NCT00262405
Drug: azathioprine/prednisone
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00440323
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablet matching SB-649868 or Placebo capsule matching Zolpidem will be available.
Trial: NCT00861185
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo looks identical to active study medication and will be dosed according to the same dosing regimen
Trial: NCT01065935
Drug: Normal Saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered by nebulization once daily for 5 days
Trial: NCT03619213
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matching dapagliflozin 10 mg
Trial: NCT00274391
Drug: 7% NaCl
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00274391
Drug: Amiloride HCl
RxNorm normalized name: amiloride HCl
DrugBank: Amiloride (DB00594)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00340431
Drug: MSP1(42)-FVO & MSP1(42)-3D7
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00994617
Drug: Hydrochlorothiazide switched over with Losartan at 8 weeks
RxNorm normalized name: hydrochlorothiazide / losartan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrochlorothiazide 12.5-25mg crossed over with Losartan 50-100mg
Trial: NCT00811252
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: capsules; daily; orally
Trial: NCT00592683
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT02651610
Drug: Taxane
RxNorm normalized name: Taxanes
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug: Taxane Other names: Paclitaxel. Taxotere, Taxotere, Docecad, Taxol
Trial: NCT01854177
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00787007
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: capsule, oral, single dose
Trial: NCT01476930
Drug: conventional migraine drug treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nortriptyline ,propranolol ,ergotamine , sumatriptan tablets
Trial: NCT02904226
Drug: JTX-2011
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Specified dose on specified days
Trial: NCT00296322
Drug: cisplatin, mitomycin-C, doxifluridine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mf: Mitomycin-C 20mg/m2 intravenously (3-6 weeks after surgery) Doxifluridine 460-600mg/m2/day per oral for 3 months (started 4 weeks after surgery)~iceMFP: Cisplatin 100mg with 1L of normal saline intraperitoneally for 2 hours during surgery Mitomycin-C 15mg/m2 intravenously (1 day after surgery) Doxifluridine 460-600mg/m2/day per oral(started at 4 weeks after surgery and administered a total of 12 months) Cisplatin 60mg/m2 intravenously monthly for 6 months (started at 4 weeks after surgery)
Trial: NCT02152969
Drug: Chlorthalidone
RxNorm normalized name: Chlorthalidone
DrugBank: Chlorthalidone (DB00310)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00443508
Drug: adding Certican to therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00446030
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 50 mg/m\^2 administered IV on Day 1 for Cycles 1-6
Trial: NCT00446030
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 500 mg/m\^2 administered IV on Day 1 for Cycles 1-6
Trial: NCT02635230
Drug: Combination of chronic oral anticoagulation and a P2Y12 inhibitor with or without aspirin.
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02420457
Drug: Epidural steroid injection as determined by routine care provider
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Betamethasone Triamcinolone Dexamethasone Methylprednisolone Lidocaine Bupivacaine Ropivacaine Normal saline
Trial: NCT04372264
Drug: Ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: third group: 400 mg Ibuprofen (İntrafen 400 mg vial-Gen-İstanbul) intravenous (IV) was given 70 patients, which determined to be applied as a group.
Trial: NCT00982566
Drug: ABT-263
RxNorm normalized name: ABT-925
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Part 1: Single (oral) dose of 250 mg of Formulation B1 vs. single (oral) dose of 250 mg of Formulation A
Trial: NCT00982566
Drug: ABT-263
RxNorm normalized name: ABT-925
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Part 1 continued. Single (oral) dose of 250 mg of Formulation B2 vs. single (oral) dose of 250 mg of Formulation A
Trial: NCT00982566
Drug: ABT-263
RxNorm normalized name: ABT-925
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Part 1: Single (oral) dose of 200 mg of Formulation C vs. single (oral) dose of 200 mg of Formulation A
Trial: NCT01473524
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo tablets were administered orally once daily.
Trial: NCT02473406
Drug: Thymosin Alpha 1
RxNorm normalized name: Thymosin alpha 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In addition to the standard treatment, thymosin therapy will be started after admission: 1.6mg I.H q12h for the first 7 days and 1.6mg I.H, qd for the following 7 days or until discharge.
Trial: NCT02473406
Drug: normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo inject will be given at the same dose as Thymosin in addition to the standard treatment.
Trial: NCT00269763
Drug: Fentanyl Transdermal Therapeutic System (TTS)
RxNorm normalized name: fentanyl Transdermal System
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00699790
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets, Oral, 0mg, once daily, 12 weeks
Trial: NCT03717740
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will take an inert tablet similar in appearance, color, and consistency from 12+ and 17 weeks of pregnancy until 34 weeks of pregnancy
Trial: NCT01358383
Drug: naproxen
RxNorm normalized name: Naproxen
DrugBank: Naproxen (DB00788)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 250mg, oral dose
Trial: NCT01243931
Drug: OCT-guided laser phototherapeutic keratectomy
RxNorm normalized name: Urimar Reformulated Oct 2013
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preoperative measurements from the OCT are used to assist the calculation in deciding the laser depth settings for removal of anterior corneal opacities and defects in the phototherapeutic PTK procedure. The surgeon uses the OCT data to plan a range of treatment parameters to remove most of the opacity while preserving at least 250 microns of residual corneal stroma.
Trial: NCT04073615
Drug: Trifluridine/Tipiracil
RxNorm normalized name: TRIFLURIDINE/TIPIRACIL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Film-coated tablets
Trial: NCT03693872
Drug: Dopaminergic Agonist + Apomorphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apomorphine (5 mg/ml), supplied as solution for infusion in a 10 ml glass ampoule Hourly flow rate adjusted during the whole duration of the study to obtain the best effect in each patient and associated with dopaminergic agonists
Trial: NCT00668005
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo
Trial: NCT01733329
Drug: Folic Acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: At cord clamping 2 tablets (10 mg) were placed in the patient´s buccal space by anesthesiologist.
Trial: NCT00482001
Drug: Placebo (cornstarch)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02956655
Drug: Insulin intensive therapy: Human Insulin (Novolin-R, Novo Nordisk)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Human Insulin (Novolin-R, Novo Nordisk)~Device: H-Tron Plus V100; Disetronic Medical System, Burgdorf, Switzerland~The target fasting plasma glucose is set below 6.1mmol/l and the postprandial blood glucose below 8.0 mmol/l. If the glucose target cannot be achieved within 2 weeks or the subjects are not tolerated with this therapy, these members will be exclude from the study and they will receive other treatment according the standard treatment guidelines. After intervention, all the accomplished patients will undergo a 1 year period follow-up. Lifestyle guidance will be offered throughout the follow-up.
Trial: NCT04032366
Drug: inhaled nitric oxide
RxNorm normalized name: nitric oxide Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: using of inhaled nitric oxide
Trial: NCT03238924
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline nasal spray, self-administered
Trial: NCT00780403
Drug: Zyrtec® (cetirizine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zyrtec® (cetirizine) Chewable Tablets, 1 tablet (5 mg), oral administration, single day
Trial: NCT01171118
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The administration of placebo versus physostigmine was untertaken in the same sedation conditions on the alternate day in each subject (and with both room air and oxygen)
Trial: NCT02119819
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered SC
Trial: NCT01302275
Drug: Oxcarbazepine
RxNorm normalized name: Oxcarbazepine
DrugBank: Oxcarbazepine (DB00776)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oxcarbazepine capsules 300 mg is gradually increased from 300 mg/day to 2400 mg/day Placebo capsules increase from 1/day to 8/day
Trial: NCT03269318
Drug: Montelukast or Salmeterol or Theophylline or Steroid
RxNorm normalized name: Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication will be patient specific according to their current medication, clinical symptoms and genotype. It will be from a choice of; leukotriene receptor antagonist (montelukast), long-acting beta2 agonist (salmeterol), theophylline or increase dose of inhaled steroid.
Trial: NCT02604966
Drug: DHA - PPQ group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral treatment with 3-day course of DHA - PPQ. Randomization is done by blocks of ten.
Trial: NCT02732951
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01826214
Drug: LDE225
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LDE225 will be supplied as 200 mg capsules by Novartis. Patients will receive study treatment on an outpatient basis. LDE225 will be dispensed every two weeks for the first four weeks and at the start of every four weeks thereafter, as needed.
Trial: NCT04030195
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide is used for lymphodepletion (500 mg/m\^2/day, Days -5 to -3).
Trial: NCT02463942
Drug: Doxycycline
RxNorm normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Beside symptomatic therapy, patients will receive oral Doxycycline 100 mg, Doxy® twice daily.
Trial: NCT02463942
Drug: Symptomatic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive symptomatic therapy with antipyretics, analgetics, antiemetics, and parenteral hydration: metamizole, Analgin®, paracetamol, Lekadol®, thiethylperazine, Kytril®, saline.
Trial: NCT02455115
Drug: Norepinephrine
RxNorm normalized name: Norepinephrine
DrugBank: Norepinephrine (DB00368)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Infusion rate of norepinephrine is raised and lowered, respectively, in order to reach MAP 60, 75 and 90 mmHg in patients already requiring vasopressor for adequate blood pressure control.
Trial: NCT02455115
Drug: Chromium ethylenediaminetetraacetic acid
RxNorm normalized name: ethylenediaminetetraacetate
DrugBank: Edetic acid (DB00974)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Extraction of 51Cr-EDTA measured for FF and GFR
Trial: NCT00654927
Drug: Fampridine-SR b.i.d. (Twice Daily)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dosage form - tablets.
Trial: NCT03645187
Drug: FOLFERI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FOLFERI regimen
Trial: NCT03645187
Drug: Folferi and celecoxib
RxNorm normalized name: amlodipine and celecoxib
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Folferi regimen and celecoxib
Trial: NCT03916068
Drug: Trental Pill
RxNorm normalized name: Trental Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trental 400 mg three times daily, in combination with Vitamin E 400 IU twice daily
Trial: NCT01543490
Drug: ISV-305
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone in DuraSite® 2 twice daily for 2 weeks
Trial: NCT03018015
Drug: Ibuprofen 400 mg oral powder
RxNorm normalized name: ibuprofen 400 MG
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03018015
Drug: Ibuprofen 400 mg film-coated tablet
RxNorm normalized name: ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03018015
Drug: Ibuprofen 400 mg soft capsule
RxNorm normalized name: ibuprofen 400 MG
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01024244
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered po BID, prior to morning and evening meals for 12 weeks.
Trial: NCT01609933
Drug: ABT-267
RxNorm normalized name: ABT-925
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABT-267 (tablets)
Trial: NCT03340350
Drug: Minocycline
RxNorm normalized name: Minocycline
DrugBank: Minocycline (DB01017)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Minocycline capsule
Trial: NCT01902017
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg placebo PO bid
Trial: NCT02256111
Drug: Androgen deprivation therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00716521
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single oral dose placebo
Trial: NCT01587963
Drug: Ascorbic Acid
RxNorm normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 66mg/kg/hour of peripheral intravenous Vitamin C infusion for 24 hour duration, maximum total of 200 grams
Trial: NCT01976143
Drug: NKTR-102
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01922843
Drug: DP001 softgel capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02347358
Drug: IV r-tPA
RxNorm normalized name: pantolactone, (R)-
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intravenous recombinant human tissue plasminogen activator
Trial: NCT01557010
Drug: DWP05195
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets, oral administration, 100mg
Trial: NCT01557010
Drug: DWP05195
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets, oral administration, 200mg
Trial: NCT01557010
Drug: DWP05195
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets, oral administration, 300mg
Trial: NCT02373930
Drug: DTG 50 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dolutegravir will be supplied as a white, film-coated, round tablet with a unit dose strength of 50 mg to be administered orally
Trial: NCT02373930
Drug: RPV 25 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rilpivirine will be supplied as a white to off-white, film-coated, round biconvex tablet with a unit dose strength of 25 mg to be administered orally
Trial: NCT02373930
Drug: DTG/RPV 50 mg/25 mg: Product Code AS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DTG/RPV will be supplied as a pink, film coated, round biconvex tablet with a unit dose strength of 50 mg DTG and 25 mg RPV to be administered orally
Trial: NCT02373930
Drug: DTG/RPV 50 mg/25 mg: Product Code AM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DTG/RPV will be supplied as a pink, film coated, oval, biconvex tablet with a unit dose strength of 50 mg DTG and 25 mg RPV to be administered orally
Trial: NCT02373930
Drug: DTG/RPV 50 mg/25 mg: Product Code AQ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DTG/RPV will be supplied as a pink, film coated, round, biconvex tablet with a unit dose strength of 50 mg DTG and 25 mg RPV to be administered orally
Trial: NCT02373930
Drug: DTG/RPV 50 mg/25 mg: Product Code AK
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DTG/RPV will be supplied as pink, film coated, oval, biconvex tablet with a unit dose strength of 50 mg DTG and 25 mg RPV to be administered orally
Trial: NCT02373930
Drug: DTG/RPV 50 mg/25 mg: Product Code AR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DTG/RPV will be supplied as a pink, film coated, round, biconvex tablet with a unit dose strength of 50 mg DTG and 25 mg RPV to be administered orally
Trial: NCT02537860
Drug: Intravenous (IV) fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients will be given 1 μg/kg intravenous (IV) fentanyl as premedication
Trial: NCT01922843
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03486236
Drug: Matched Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebos matched to VX-440, TEZ, and IVA.
Trial: NCT03361501
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 x 1 g capsules administered orally once daily for 26 weeks
Trial: NCT03139370
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Administered intravenously
Trial: NCT01998646
Drug: ASP4058
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tablet
Trial: NCT01998646
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tablet
Trial: NCT01910844
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Metronomic cyclophosphamide per os 150 mg from day 1 to day 14 - total dose 2100 mg every 3 weeks
Trial: NCT00817414
Drug: LCI699-matching placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LCI699-matching placebo oral capsules
Trial: NCT00817414
Drug: LCI699
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LCI699 oral capsules
Trial: NCT04562324
Drug: SSRI or SNRI or benzodiazepines or tricyclic antidepressants or other antidepressants or antipsychotics or other sedative-hypnotics
RxNorm normalized name: Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medications to relieve anxiety
Trial: NCT01358500
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous infusion using STANPUMP
Trial: NCT02015819
Drug: leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given orally